CD4 and glioblastoma: These results again support our hypothesis that CD4+ T cells obtained from M002-treated mice harboring GBM demonstrated increased capacity to control established orthotopic GBM, and that the survival benefit was not solely attributable to the increased magnitude of the intratumoral immune response.